Y. James Kang

Personal Home Page

http://browncancercenter.org/research/researcher.aspx?id=1668

Articles in Scholarly Journals [Incomplete List]

  1. Antioxidant defense against anthracycline cardiotoxicity by metallothionein
    Cardiovascular Toxicology, vol. 7, no. 2, pp. 95–100, 2007
  2. Changes in copper and zinc status and response to dietary copper deficiency in metallothionein-overexpressing transgenic mouse heart?
    The Journal of Nutritional Biochemistry, vol. 18, no. 11, pp. 714–718, 2007
  3. Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions
    Biochemical and Biophysical Research Communications, vol. 360, no. 1, pp. 286–289, 2007
  4. Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice
    Journal of Experimental Medicine, vol. 204, no. 3, pp. 657–666, 2007
  5. Heavy Metal Ions in Normal Physiology, Toxic Stress, and Cytoprotection
    Annals of the New York Academy of Sciences, vol. 1113, no. 1, pp. 159–172, 2007
  6. Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
    Current Neurovascular Research, vol. 4, no. 4, pp. 289–294, 2007
  7. Calcineurin Activation Is Not Necessary for Doxorubicin-Induced Hypertrophy in H9c2 Embryonic Rat Cardiac Cells: Involvement of the Phosphoinositide 3-Kinase-Akt Pathway
    Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 934–940, 2006
  8. Cardiac Hypertrophy: A Risk Factor for QT-Prolongation and Cardiac Sudden Death
    Toxicologic Pathology, vol. 34, no. 1, pp. 58–66, 2006
  9. Attenuation by Metallothionein of Early Cardiac Cell Death via Suppression of Mitochondrial Oxidative Stress Results in a Prevention of Diabetic Cardiomyopathy
    Journal of the American College of Cardiology, vol. 48, no. 8, pp. 1688–1697, 2006
  10. Metallothionein Disulfides Are Present in Metallothionein-overexpressing Transgenic Mouse Heart and Increase under Conditions of Oxidative Stress
    Journal of Biological Chemistry, vol. 281, no. 2, pp. 681–687, 2005
  11. Zinc prevention and treatment of alcoholic liver disease
    Molecular Aspects of Medicine, vol. 26, no. 4-5, pp. 391–404, 2005
  12. Vasoreactivity in an adult rat model of marginal copper deficiency
    Nutrition Research, vol. 25, no. 2, pp. 177–186, 2005
  13. Parameter optimization and characteristic analysis of a polymer microring resonant wavelength multiplexer
    Optics & Laser Technology, vol. 37, no. 4, pp. 337–344, 2005
  14. Metallothionein transfers zinc to mitochondrial aconitase through a direct interaction in mouse hearts
    Biochemical and Biophysical Research Communications, vol. 332, no. 3, pp. 853–858, 2005
  15. Modulation of Cytochrome c Oxidase-Va Is Possibly Involved in Metallothionein Protection from Doxorubicin Cardiotoxicity
    Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 3, pp. 1314–1319, 2005
  16. Inhibition of Superoxide Generation and Associated Nitrosative Damage Is Involved in Metallothionein Prevention of Diabetic Cardiomyopathy
    Diabetes, vol. 54, no. 6, pp. 1829–1837, 2005
  17. Cardiac Functional Analysis by Electrocardiography, Echocardiography and in situ Hemodynamics in Streptozotocin-Induced Diabetic Mice
    JOURNAL OF HEALTH SCIENCE, vol. 50, no. 4, pp. 356–365, 2004
  18. Changes in the Gene Expression Associated with Carbon Tetrachloride-Induced Liver Fibrosis Persist after Cessation of Dosing in Mice
    Toxicological Sciences, vol. 79, no. 2, pp. 404–410, 2004
  19. Metallothionein Gene Therapy for Chemical-Induced Liver Fibrosis in Mice
    Molecular Therapy, vol. 10, no. 6, pp. 1130–1139, 2004
  20. S-adenosylhomocysteine sensitizes to TNF-? hepatotoxicity in mice and liver cells: A possible etiological factor in alcoholic liver disease
    Hepatology, vol. 40, no. 4, pp. 989–997, 2004
  21. Prevention of Alterations in Intestinal Permeability Is Involved in Zinc Inhibition of Acute Ethanol-Induced Liver Damage in Mice
    Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 880–886, 2003
  22. Biotechnology-Derived Cardiovascular Therapeutics and Toxicity
    Cardiovascular Toxicology, vol. 3, no. 1, pp. 1–4, 2003
  23. Cell Death and Diabetic Cardiomyopathy
    Cardiovascular Toxicology, vol. 3, no. 3, pp. 219–228, 2003
  24. Diabetes Enhances Lipopolysaccharide- Induced Cardiac Toxicity in the Mouse Model
    Cardiovascular Toxicology, vol. 3, no. 4, pp. 363–372, 2003
  25. Myocardial Toxicity of Arsenic Trioxide in a Mouse Model
    Cardiovascular Toxicology, vol. 2, no. 1, pp. 63–74, 2002
  26. Inhibition of Tumor Necrosis Factor-alpha-Dependent Cardiomyocyte Apoptosis by Metallothionein
    Cardiovascular Toxicology, vol. 2, no. 3, pp. 209–218, 2002
  27. Cardiovascular Toxicity of Particulate Air Pollution
    Cardiovascular Toxicology, vol. 2, no. 4, pp. 233–236, 2002
  28. Elevation of Serum Endothelins and Cardiotoxicity Induced by Particulate Matter (PM2.5) in Rats with Acute Myocardial Infarction
    Cardiovascular Toxicology, vol. 2, no. 4, pp. 253–262, 2002
  29. Chemical Research in Toxicology, vol. 15, no. 1, pp. 1–6, 2002
  30. Zinc Inhibition of Caspase-3 Activation Does Not Protect HeLa Cells from Apoptotic Cell Death
    Toxicology and Applied Pharmacology, vol. 175, no. 1, pp. 89–93, 2001
  31. Oxidative Stress and Diabetic Cardiomyopathy: A Brief Review
    Cardiovascular Toxicology, vol. 1, no. 3, pp. 181–194, 2001
  32. Alterations in Hypertrophic Gene Expression by Dietary Copper Restriction in Mouse Heart
    Proceedings of the Society for Experimental Biology and Medicine, vol. 223, no. 3, pp. 282–287, 2000
  33. Suppression by Metallothionein of Doxorubicin-induced Cardiomyocyte Apoptosis through Inhibition of p38 Mitogen-activated Protein Kinases
    Journal of Biological Chemistry, vol. 275, no. 18, pp. 13690–13698, 2000
  34. Metallothionein Inhibits Peroxynitrite-induced DNA and Lipoprotein Damage
    Journal of Biological Chemistry, vol. 275, no. 50, pp. 38957–38960, 2000
  35. Induction of Antioxidants by Adriamycin in Mouse Heart
    Biochemical Pharmacology, vol. 56, no. 1, pp. 87–93, 1998
  36. Effect of buthionine sulfoximine on the response to arsenic deprivation in female rats
    The Journal of Trace Elements in Experimental Medicine, vol. 11, no. 1, pp. 29–36, 1998
  37. Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells
    Biochemical Pharmacology, vol. 53, no. 5, pp. 747–754, 1997
  38. Alterations of the glutathione redox cycle status in fumonisin B1-treated pig kidney cells
    Journal of Biochemical Toxicology, vol. 11, no. 3, pp. 121–126, 1996
  39. Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats
    Biochemical Pharmacology, vol. 51, no. 4, pp. 567–570, 1996
  40. Cadmium resistance in A549 cells correlates with elevated glutathione content but not antioxidant enzymatic activities
    Free Radical Biology and Medicine, vol. 19, no. 6, pp. 805–812, 1995
  41. Copper deficiency increases metallothionein-I mRNA content selectively in rat liver
    The Journal of Nutritional Biochemistry, vol. 6, no. 11, pp. 572–576, 1995
  42. Weak antioxidant defenses make the heart a target for damage in copper-deficient rats
    Free Radical Biology and Medicine, vol. 17, no. 6, pp. 529–536, 1994
  43. Glutathione stimulates A549 cell proliferation in glutamine-deficient culture: The effect of glutamate supplementation
    Journal of Cellular Physiology, vol. 161, no. 3, pp. 589–596, 1994
  44. Exogenous glutathione attenuates the antiproliferative effect of buthionine sulfoximine
    Toxicology, vol. 88, no. 1-3, pp. 177–189, 1994
  45. Cadmium inhibits EGF-induced DNA synthesis but increases cellular glutathione levels in NRK-49F cells
    Toxicology, vol. 66, no. 3, pp. 325–333, 1991
  46. Increased glutathione levels in quiescent, serum-stimulated NRK-49F cells are associated not with a response to growth factors but with nutrient repletion
    Journal of Cellular Physiology, vol. 148, no. 2, pp. 197–201, 1991
  47. Glutathione content and growth in A549 human lung carcinoma cells*1
    Experimental Cell Research, vol. 187, no. 1, pp. 177–179, 1990
  48. Cadmium cytotoxicity correlates with the changes in glutathione content that occur during the logarithmic growth phase of a549-t27 cells
    Toxicology Letters, vol. 51, no. 1, pp. 23–28, 1990
  49. Cellular cadmium responses in subpopulations T20 and T27 of human lung carcinoma A549 cells
    Toxicology, vol. 61, no. 2, pp. 195–203, 1990
  50. Diamide reduces cadmium accumulation by human lung carcinoma A549 cells
    Toxicology, vol. 62, no. 1, pp. 53–58, 1990
  51. Enhanced cadmium cytotoxicity in A549 cells with reduced glutathione levels is due to neither enhanced cadmium accumulation nor reduced metallothionein synthesis
    Cell Biology and Toxicology, vol. 5, no. 3, pp. 249–259, 1989
  52. Glutathione is involved in the early cadmium cytotoxic response in human lung carcinoma cells
    Toxicology, vol. 48, no. 1, pp. 93–101, 1988